HoldsUp

Derya Unutmaz

Derya Unutmaz is a biomedical researcher working in immunology and computational biology. His published research focuses on CAR T-cell therapies for autoimmune diseases and cancer, single-cell mapping of the human immune system across the lifespan, and artificial intelligence-driven multi-omics modeling of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). He has also investigated gut microbiome-host interactions, metabolomics, and immune responses in conditions such as long COVID.

35 claims checked on air: 4 context 2 contradicted 3 overstated 23 supported 3 unverified

What they said on air

0:02:54supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

The term 'longevity escape velocity' was coined by biogerontologist Aubrey de Grey.

"So we will get to a point what's called the longevity escape velocity. This was coined by Aubrey de Grey, who, as you know, is a great aging researcher." (said at 0:02:54)

Biogerontologist Aubrey de Grey is widely documented in the scientific and bioethics literature as the originator of the concept of 'longevity escape velocity' (the hypothetical threshold where anti-aging biomedical interventions extend life expectancy faster than time passes). De Grey, who formulated the Strategies for Engineered Negligible Senescence (SENS) framework, identifies as a biomedical gerontologist and introduced the concept in discussions of radical life extension and aging repair.

0:05:15overstatedmoderateWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

GLP-1 receptor agonists add approximately 5 to 10 years to the lifespan of people who are obese or have chronic conditions.

"Or we're already starting to see that with the GLP-1 drugs, receptor agonists, which are adding about 5 to 10 years to the lifespan of people who are obese or who have chronic conditions." (said at 0:05:15)

GLP-1 receptor agonists (such as semaglutide and liraglutide) have been shown in large randomized clinical trials to significantly reduce all-cause mortality and major adverse cardiovascular events in individuals with obesity, diabetes, and established cardiovascular disease. However, the claim that they add 5 to 10 years to lifespan is substantially overstated. Actuarial modeling applying trial data (such as from the SELECT trial) to real-world populations projects average life expectancy gains of approximately 1.9 years (and ~2.0 cardiovascular event-free years), rather than 5 to 10 years.

0:16:26overstatedlowWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Self-driving cars are currently about 10 times safer than human drivers.

"And right now, self-driving cars are probably about 10 times safer, they will be maybe 100 times safer" (said at 0:16:26)

The speaker claims that self-driving cars are currently "about 10 times safer" than human drivers. Real-world safety assessments of fully autonomous vehicles (such as Waymo's Rider-Only operations) show statistically significant reductions in crash and injury rates compared to human benchmarks, but not by a factor of 10. For example, analysis of 7.14 million miles of Waymo autonomous driving reported an 80% reduction in any-injury-reported crash rates (a human crash rate 5 times higher, or ADS 5 times safer) and a 55% reduction in police-reported crash rates (2.2 times higher human rate). Analysis across 56.7 million miles demonstrated significant reductions across crash types (such as a 91% to 96% reduction in specific vehicle-to-vehicle intersection crashes), but overall safety across all conditions and operations is not 10 times safer than human drivers. Thus, the claim overstates the current safety advantage.

0:19:10supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

The AI program AlphaGo defeated the world champion in the board game Go.

"Or AlphaGo beat the world champion in Go, which is a much more difficult game." (said at 0:19:10)

The claim is supported by published literature on artificial intelligence and game theory. Google DeepMind's AlphaGo defeated top-ranked human Go world champion Lee Sedol 4–1 in March 2016 and world champion Ke Jie in May 2017. Go was long considered a major benchmark for artificial intelligence due to its vast decision space and extreme combinatorial complexity relative to games such as chess.

0:19:44supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

AI defeated chess champion Garry Kasparov in 1997.

"AI beat the chess champion Kasparov in 1997, I think, decades ago, but that was not general intelligence." (said at 0:19:44)

IBM's Deep Blue chess system defeated reigning world chess champion Garry Kasparov in a six-game match held in May 1997 in New York. The system used specialized hardware, tree search algorithms, and domain-specific heuristics rather than artificial general intelligence.

0:22:15contradictedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Humans did not have language until approximately 10,000 years ago, and writing and cognitive intelligence developed only in the last 10,000 to 20,000 years.

"We didn't have language up to, I don't know, 10,000 years ago; we didn't know how to write. This cognitive part has developed in the last maybe 10, 20,000 years." (said at 0:22:15)

The claim that humans did not have language until approximately 10,000 years ago and that cognitive intelligence only emerged in the last 10,000 to 20,000 years is contradicted by archaeological, paleoanthropological, and genetic consensus. Anatomically and cognitively modern *Homo sapiens* evolved over 100,000 to 300,000 years ago in Africa, displaying complex symbolic behavior, tool manufacturing, and language capacities tens to hundreds of thousands of years before the 10,000-year mark (for example, language and complex cognitive capacities were already established prior to human migrations out of Africa and the peopling of Australia at least 50,000 to 65,000 years ago). While the speaker's secondary mention that writing was absent prior to recent millennia is accurate (true writing systems first emerged around ~5,000 to 5,500 years ago in Mesopotamia and Egypt), spoken language and human cognitive capacities long predate the 10,000-to-20,000-year timeline.

0:41:50supportedmoderateWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

In the United States, there are approximately 12 million medical misdiagnoses each year, resulting in around 700,000 people dying or suffering from harm.

"I think they've said something like 12 million misdiagnosis. Um I think 700,000 people suffer from it, die from it, from from uh uh from misdiagnosis." (said at 0:41:50)

The speaker accurately cites landmark epidemiological estimates of diagnostic errors in the United States. A 2014 study by Singh and colleagues synthesized data across outpatient observational cohorts and estimated that diagnostic errors affect approximately 5.08% of US adults, representing approximately 12 million individuals annually. A subsequent 2024 nationwide modeling study by Newman-Toker and colleagues estimated that misdiagnoses result in approximately 795,000 cases of permanent disability or death each year (plausible range: 598,000 to 1,023,000).

0:42:31needs contextmoderateWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

AI models can detect certain tumors like breast cancer years before a radiologist can see them.

"The AI models are able to detect certain tumors like breast cancer years before a radiologist is able to to to see that." (said at 0:42:31)

Deep learning models (such as Mirai) have been developed and validated to evaluate screening mammograms read as negative by radiologists to predict the future risk of breast cancer up to 1 to 5 years in advance (achieving concordance indices of approximately 0.75–0.84 across diverse international cohorts). However, these algorithms are assessing imaging-based future risk and parenchymal features rather than directly visualizing or detecting an established, measurable tumor years before clinical diagnosis.

0:44:05unverifiedvery lowWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

A recent study published in Science found that the OpenAI o1 preview model performed significantly better than the average doctor in diagnosing medical conditions.

"Uh in fact, uh a Science paper came out recently, which was done with o1 preview model, which is a very old model... And um and they found that o1 model uh did did better than average doctor in diagnosing, like significantly better. They did didn't miss." (said at 0:44:05)

No published record matching a study in Science demonstrating that the OpenAI o1 preview model performed significantly better than the average doctor in diagnosing medical conditions was located; this does not prove the claim false.

1:00:32supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Certain childhood leukemias that were previously fatal now have cure rates between 90% and close to 100%.

"childhood leukemias, which were completely fatal, you know, couple of decades ago, are now, you know, 90% or or close to 100% curable." (said at 1:00:32)

Childhood acute lymphoblastic leukemia (ALL), which was universally fatal prior to modern multi-agent chemotherapy regimens developed in the mid-to-late 20th century, now demonstrates long-term survival and cure rates approaching or exceeding 90% in contemporary treatment protocols.

1:07:38unverifiedvery lowWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

An Australian computer scientist used AI models including ChatGPT to design an individualized mRNA vaccine that caused tumor regression in his dog diagnosed with melanoma.

"You probably heard of this story from Australia. This computer scientist um had ChatGPT and and some other AI models to develop an mRNA vaccine for his dog. His dog had I think a melanoma, and he um he got it sequenced. He took the sequence and gave it gave it to to an AI model, and the AI model designed the precise mRNA molecule that needs that the dog needs dog's immune system needs to be trained, got it synthesized, and I think it was able to apply it in 3 months. Um probably could have been shorter if there wasn't regulations, and and the tumor started to to regress, and the dog is was was alive when it was supposed to to die." (said at 1:07:38)

No published record matching the case of an Australian computer scientist using ChatGPT or other AI models to design a personalized mRNA vaccine that induced tumor regression in a dog with melanoma was located; this does not prove the claim false.

1:10:20needs contextmoderateWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

COVID-19 vaccination caused myocarditis in young people at a rate of 1 in 5,000 to 1 in 10,000.

"Yes, the vaccinated people, young people, at 1 in 5,000 to 1 in 10,000 rate got myocarditis." (said at 1:10:20)

A rate of 1 in 5,000 to 1 in 10,000 (equivalent to 100 to 200 cases per million) falls within the estimated peak incidence range for the highest-risk subgroup—specifically adolescent and young adult males (aged 12–29) following a second mRNA vaccine dose (especially with mRNA-1273 or shorter interdose intervals). However, attributing this rate to "young people" in general requires qualification, as the incidence is significantly lower in young females (fewer than 20 cases per million, or <1 in 50,000) and across all young vaccinees when combining both sexes and all doses.

1:10:55contradictedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Only about 1 in 5 to 1 in 10 people who take statins for high cholesterol derive a true cardiovascular benefit.

"we give statins to anyone who has high cholesterol. So I I think like one out of five or one out of 10 people truly benefit from that." (said at 1:10:55)

Large-scale systematic reviews and meta-analyses of randomized clinical trials show that for primary prevention of cardiovascular disease, statins reduce composite cardiovascular outcomes by an absolute risk difference (ARD) of approximately 1.28% over 1 to 6 years of follow-up (equating to roughly 1 in 78 individuals avoiding an event, or a Number Needed to Treat [NNT] of ~78). For myocardial infarction, the ARD is 0.85% (NNT ~118), and for all-cause mortality, it is 0.35% (NNT ~285). The claim that 1 in 5 (20%) to 1 in 10 (10%) individuals derive a true cardiovascular benefit substantially overestimates the absolute proportion of patients who avoid a major cardiovascular event over typical trial durations, which is closer to 1% to 2% (1 in 50 to 1 in 100).

1:13:35unverifiedvery lowWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

A machine learning study utilizing UK Biobank data from 500,000 participants was able to predict approximately 1,000 diseases before clinical onset.

"There was a study from um UK Biobank. Um UK has this amazing biobank with 500,000 people, uh lots of data sets, incredible data sets. And so and this was actually done I think more than a year ago with models that were a year or two years old. They took a lot of that data, and they were able to predict about thousand diseases before they happened." (said at 1:13:35)

No published record matching the claim that a machine learning model utilizing UK Biobank data predicted approximately 1,000 diseases before onset was located; this does not prove the claim false. While the UK Biobank includes approximately 500,000 participants and has been widely used to train machine learning and multi-omics models for incident disease prediction, published multi-disease prediction models typically evaluate dozens to a few hundred distinct conditions rather than approximately 1,000 individual diseases.

1:15:13supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Certain species of whales have lifespans reaching hundreds of years.

"For some whales, it's hundreds of years." (said at 1:15:13)

Scientific literature confirms that certain whale species, particularly the bowhead whale (Balaena mysticetus), can live for more than 200 years, making them the longest-lived mammals known.

1:16:40supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

There are more than 1,000 metabolites present in the human bloodstream.

"there are more than a thousand metabolites in our bloodstream" (said at 1:16:40)

The claim is supported. Systematic profiling of the human serum metabolome using multi-platform analytical technologies (NMR, GC-MS, and LC-MS) and literature curation has identified thousands of distinct metabolites present in human blood. The Human Serum Metabolome Project documented over 4,200 confirmed and highly probable compounds in human serum.

1:24:45supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Children with progeria age prematurely to resemble 80- or 90-year-olds by the age of 7 or 8 due to a single point mutation.

"there is a disease called progeria. These children get aged by the age of seven, eight; they become like an 80-, 90-year-old because of a single point mutation in one of their genes, because they lose their ability to repair" (said at 1:24:45)

The speaker's claim is supported by clinical genetics literature. Hutchinson-Gilford progeria syndrome (HGPS) is classically caused by a de novo heterozygous point mutation in the LMNA gene (most commonly c.1824C>T, p.Gly608Gly). This mutation activates a cryptic splice site producing a toxic truncated lamin A protein called progerin. Progerin disrupts the nuclear envelope, interferes with the DNA damage response and DNA repair mechanisms, and leads to dramatic accelerated physiological aging phenotypes (including severe cardiovascular disease, alopecia, lipodystrophy, and skin changes), giving affected children the physical appearance and cardiovascular pathologies typical of very advanced age by middle-to-late childhood.

1:32:30supportedmoderateWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Elephants rarely get cancer because they have multiple copies of the p53 gene, which acts as a guardian of the genome preventing mutations.

"Like elephants rarely get cancer, right? Because they have this gene called p53; they have multiple copies of that. p53 is kind of like the guardian of the genome. You know, it prevents the genome from getting too much mutations and prevents cancer. So somehow elephants have—I don't know how many copies, but they get very rarely cancer." (said at 1:32:30)

Comparative genomic and cellular studies confirm that elephants have a low incidence of cancer despite their large body size and long lifespan (an example of Peto's paradox). While humans carry one copy (2 alleles) of the TP53 tumor suppressor gene—often referred to as the guardian of the genome—African elephants possess at least 20 copies (40 alleles, including 19 retrogenes). These duplicated copies contribute to an enhanced DNA damage response and heightened p53-mediated apoptosis, which clears damaged cells and protects against cancer development.

1:33:00supportedvery lowWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Naked mole-rats can live 30 to 40 years compared to regular rats that live only a couple of years, in part due to a mutation in the immune gene cGAS involved in immune optimization and DNA repair.

"Naked mole-rats, you probably know that very well, you know, they're like rats, they live underground, but normal rats live a couple of years and these guys live 30, 40 years. So it turns out they have some mutation in some immune gene called cGAS that's also involved in immune optimization and DNA repair." (said at 1:33:00)

Naked mole-rats (*Heterocephalus glaber*) are well-documented to have an exceptionally long lifespan exceeding 30 to 37 years, compared to typical laboratory and wild rats that live only 2 to 3 years. Research published in *Science* (2025) demonstrated that naked mole-rat cyclic GMP-AMP synthase (cGAS)—a classical innate immune DNA-sensing enzyme—harbors evolutionary amino acid alterations (a four-amino-acid difference compared to human and mouse homologs) that remove its normal suppressive effect on homologous recombination DNA repair. This unique cGAS variant enhances chromatin retention after DNA damage, promotes RAD50 recruitment to facilitate DNA double-strand break repair, antagonizes cellular senescence, and contributes to lifespan extension. Because the supporting evidence is derived from animal and mechanistic molecular biology models, the GRADE certainty is very low.

1:36:10supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

TNF receptors can initiate either a survival signal or a cell death/suicide signal depending on the cellular context.

"like in the immune system, we have these receptors called TNF receptors or whatever, they can have a survival signal or a death signal, suicide signal, depending on the context of the cell." (said at 1:36:10)

Tumor necrosis factor (TNF) receptor signaling is a well-established molecular paradigm capable of driving either cell survival or programmed cell death (apoptosis or necroptosis), depending on the signaling complex assembled and downstream cellular context. Activation of TNFR1 triggers membrane-bound Complex I (involving TRADD, RIPK1, and TRAF2) to activate NF-κB and MAP kinase pathways, promoting pro-survival genes. If this initial survival response is compromised or modified, a secondary cytoplasmic complex (Complex II, containing FADD and caspase-8) forms to initiate apoptosis, or necroptosis if caspases are inhibited.

1:36:35supportedvery lowWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

If Yamanaka factors are active continuously, they can cause cancer and teratomas.

"these things called Yamanaka factors, where you can generate a stem cell from a normal cell, right? So like complete regeneration. But the problem is that they can also cause cancer, because they only need to be active in certain time. If they're active all the time, they can cause teratomas and things like that." (said at 1:36:35)

The speaker correctly states that continuous or unconstrained activation of the Yamanaka reprogramming factors (OCT4, SOX2, KLF4, and c-MYC) in vivo leads to tumor and teratoma formation. Seminal animal studies demonstrated that sustained induction of these four transcription factors in mice results in multi-organ teratomas and loss of cellular identity. Consequently, regenerative approaches rely on transient, cyclic, or partial reprogramming to achieve rejuvenation or tissue repair without inducing tumorigenesis. Because this body of evidence is established primarily in preclinical animal models and in vitro systems, the GRADE certainty is very low.

1:41:07supportedmoderateWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Only about 300 living people worldwide are supercentenarians aged 110 and older.

"only 300 people in the world are 110 and older. Why is that? Why not the rest of the 8 billion, right?" (said at 1:41:07)

Demographic and genomic studies of extreme longevity estimate that roughly 300 to 500 living supercentenarians (individuals aged 110 and older) exist worldwide at any given time. Because age validation requires extensive official documentation, only a fraction of this estimated total (typically around 50 to 100 individuals) are formally verified at a single point in time. For example, a 2014 study on supercentenarian genomics noted 74 validated living supercentenarians worldwide at the time of writing.

1:42:08needs contexthighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Dolly the sheep, cloned in the late 1990s, was the first cloned sheep.

"The first moment was, uh, the, um, the sheep, uh, that's called Dolly. Uh, you probably know it was the first cloned sheep. Um, it was 1996, '97, or something like that." (said at 1:42:08)

The claim is partially accurate but requires qualification. Dolly the sheep, born in July 1996 (with results published in 1997), was famously the first mammal cloned from an *adult somatic cell* (specifically, a mammary gland cell). However, she was not the first cloned sheep. Cloned sheep had been produced a decade earlier in 1986 by Steen Willadsen using nuclear transfer from embryonic blastomeres. Dolly's scientific breakthrough was demonstrating that an adult differentiated somatic cell nucleus could be reprogrammed to control full embryonic development.

1:43:11supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

The Yamanaka factors, which allow reprograming a somatic cell into an induced pluripotent stem cell, were discovered in 2006.

"And then the second, of course, uh, uh, the the Yamanaka factors, uh, in 2006, I think. Um, and that was the moment that, uh, that we knew, um, that we could completely erase the, um, sort of the age of the cell on a cellular level and then bring it back to a pluripotent stem cell level" (said at 1:43:11)

The discovery of induced pluripotent stem cells (iPSCs) and the four reprogramming transcription factors (OCT3/4, SOX2, KLF4, and c-MYC, collectively known as the Yamanaka factors) was published by Kazutoshi Takahashi and Shinya Yamanaka in 2006. This work demonstrated that differentiated somatic cells (such as mouse fibroblasts) could be reprogrammed back into a pluripotent stem cell state using a defined set of factors.

1:50:45supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Clinical trials in Japan have started using induced pluripotent stem cell technology derived from Yamanaka factors in human patients.

"In fact, I I think there was just a recent study that started in Japan using the Yamanaka factors, uh, uh, in in clinical trials because, you know, it was not a very controlled system." (said at 1:50:45)

Clinical studies and trials using induced pluripotent stem cell (iPSC) technology—originally discovered by Shinya Yamanaka using reprogramming transcription factors (Yamanaka factors)—have taken place in Japan. The first-in-human trial using autologous iPSC-derived cells was initiated in Japan for neovascular age-related macular degeneration (reported in 2017), where skin fibroblasts were reprogrammed into iPSCs and differentiated into retinal pigment epithelial sheets for transplantation. Subsequent trials in Japan have also commenced for conditions such as spinal cord injury and Parkinson's disease.

1:52:00supportedvery lowWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Jennifer Doudna's lab recently developed a new genome-editing tool for bacteria superior to standard CRISPR.

"Like, of course, we have CRISPR now, but actually Doudna's lab just came out with something even better for bacteria for genome editing." (said at 1:52:00)

Jennifer Doudna's laboratory, in collaboration with colleagues, developed DNA-editing all-in-one RNA-guided CRISPR-Cas transposase (DART) systems along with environmental transformation sequencing (ET-seq). Unlike standard CRISPR-Cas nucleases (such as Cas9), which generate double-strand breaks that are frequently lethal to bacteria lacking robust non-homologous end-joining pathways, DART leverages CRISPR-associated transposases (CASTs) to perform programmable, site-specific integration of large DNA cargos directly into targeted bacterial genomes within mixed microbial communities.

1:52:35supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Immune cells can be engineered in culture to perform biological logic operations such as AND, OR, and NOT gates based on specific molecular inputs.

"We can program immune cells in in in culture. Like we can give a a drug, it will shut down their response. Or we can create AND/OR gates and NOT gates: If they see two molecules, then they respond; if they see one, they don't." (said at 1:52:35)

Synthetic biology and cellular immunotherapy enable immune cells (such as CAR T cells) to be engineered in vitro with Boolean logic circuits (AND, OR, and NOT/INHIBIT gates) as well as drug-inducible safety switches. For instance, split-signaling CARs or synthetic Notch (synNotch) receptor systems can be designed as AND gates (requiring two target antigens to activate killing), inhibitory CARs (iCARs) function as NOT gates (suppressing activation if a healthy-tissue antigen is encountered), and multi-specific CARs act as OR gates (triggering killing if either antigen is present).

2:01:20supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

The UK Biobank collected biological and health data on 500,000 people.

"UK Biobank has done it for 500,000 people. You can do it for a million people." (said at 2:01:20)

The UK Biobank is a large prospective cohort study that recruited approximately 500,000 participants aged 40 to 69 across the United Kingdom. It collected extensive biological samples, physical and phenotypic measurements, lifestyle data, genetic information, and longitudinal health outcomes via medical record linkage.

2:02:50supportedmoderateWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Multiple studies demonstrate that higher levels of optimism improve aging outcomes and longevity.

"By the way, being optimistic is one of the best things you can do for for aging, and study after study show that. So being able to absorb, um, bad things that happen to you and then keep keep going. So resilience." (said at 2:02:50)

Multiple large prospective cohort studies and meta-analyses consistently show that higher levels of dispositional optimism are associated with improved aging outcomes, reduced all-cause mortality, and increased longevity. A 2019 meta-analysis of prospective cohort studies involving 229,391 participants found that optimism was significantly associated with a lower risk of all-cause mortality (RR 0.86, 95% CI 0.80–0.92) and cardiovascular events (RR 0.65, 95% CI 0.51–0.78). Furthermore, analyses from the Nurses' Health Study and the Veterans Affairs Normative Aging Study demonstrated that individuals in the highest versus lowest optimism quartiles had an 11% to 15% longer lifespan and 1.5- to 1.7-fold greater odds of reaching exceptional longevity (age 85 or older), associations that persisted after adjusting for health behaviors and baseline medical conditions.

2:02:55needs contextmoderateWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Epigenetic aging clocks measured in blood largely reflect the proportion of differentiated effector T cells accumulating in old age versus naive T cells.

"Usually they're done through through blood analysis, but in the blood you have, uh, like, you know, I work with T cells, so you have these cells that we call effector cells that have, um, lots of epigenetic change because they differentiated and they continue to accumulate in in old age. And then you have these naive cells that have, you know, more pristine, uh, kind. So it's a combination. So depending on, um, what that combination is is going to affect the output of of the, um So you you you can actually just look at the proportion of your, uh, T cell differentiated T cells, you'll probably get the same same kind of information." (said at 2:02:55)

Blood-based epigenetic clocks are significantly influenced by age-associated shifts in immune cell composition, particularly the decline in naive T cells and accumulation of differentiated effector memory T cells. Purified naive CD8+ T cells score 15 to 20 years younger by epigenetic clocks than effector memory CD8+ T cells from the very same donor. However, claiming that clocks solely or largely reflect cell proportions overstates the case: isolated, homogenous naive T cells still show progressive epigenetic aging as donors age, demonstrating that standard blood epigenetic clocks capture two independent phenomena simultaneously: cell-intrinsic epigenetic aging and changing leukocyte subset composition.

2:06:33overstatedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Partial epigenetic reprogramming clinical trials are being conducted in patients with glaucoma.

"Like this partial reprogramming trial they're doing, it's it's done for glaucoma patients, I I guess, uh, because that happens in old age, right?" (said at 2:06:33)

The claim that partial epigenetic reprogramming clinical trials are currently being conducted in human patients with glaucoma overstates the clinical progress of this research. Partial epigenetic reprogramming (using Oct4, Sox2, and Klf4, or OSK gene therapy) has shown success in restoring vision in animal models (mice and non-human primates) of glaucoma and optic nerve injury. However, as of recent reviews, these therapies remain in preclinical development, and human clinical trials in glaucoma patients have not yet been conducted.

2:07:10supportedmoderateWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

In old age, individuals accumulate CMV-specific T cells, which in some individuals can expand to occupy 20% to 30% of all T cells dedicated to a single CMV peptide.

"Like, for example, in old age you you accumulate these CMV-specific T cells. Um, CMV is a virus that you can't really get rid of, so the immune system constantly have to keep it under check. Um, and those immune cells, they kind of become like missionaries. They should retire, but they keep on expanding, and some individuals might have like 20, 30% of all their T cells just dedicated to like one peptide of this this CMV." (said at 2:07:10)

Human immunology studies demonstrate that latent cytomegalovirus (CMV) infection drives 'memory inflation' over a person's lifespan. In older adults, persistent immune surveillance against CMV leads to large clonal expansions of CD8+ T cells, where a massive fraction (often reaching up to 10% to >20-30% of circulating CD8+ T cells in specific individuals) is targeted against a single immunodominant CMV peptide epitope.

2:08:00supportedmoderateWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Accumulated CMV-specific T cells in older age are differentiated, have shorter telomeres, and are epigenetically closed.

"and they cause inflammation because they're they're active, and, um, and they don't give place for the young guys to come in. Uh, and they're they are epigenetically, you know, closed because, um, they're differentiated, their telomeres are shorter." (said at 2:08:00)

The statement accurately reflects established immunological findings on cytomegalovirus (CMV)-induced immunosenescence. Chronic CMV infection drives massive clonal expansion of CMV-specific CD8+ T cells (memory inflation), skewing the T-cell repertoire toward terminally differentiated effector memory (TEMRA/CD28-CD57+) phenotypes. Studies demonstrate that CMV-specific CD8+ T cells in older individuals exhibit significantly shorter telomeres due to repeated antigen-driven proliferation and undergo progressive epigenetic and transcriptional remodeling associated with terminal differentiation and cellular senescence.

2:33:22supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Standard clinical laboratory reference ranges for biomarkers like cholesterol, glucose, and sodium are determined based on population averages rather than individualized baselines.

"For example, the lab values, like you go and measure your cholesterol, glucose, sodium, whatever, they always give you a range, right? So if it's within this range, it's normal. Well, how do you know that? Because you can be at the top of the range, that might be your abnormal, somebody else's normal. Somebody might be a little bit over the normal and might still be okay, or vice versa, because we don't know the level on a personalized level. So we calculate population-based." (said at 2:33:22)

Standard clinical laboratory reference intervals (ranges) for routine biochemical markers are conventionally established from healthy reference populations (typically encompassing the central 95% of values in a reference sample group), rather than personalized baselines. Because within-subject biological variation is often narrower than between-subject population variation (demonstrated by low index of individuality for many routine analytes such as lipids and liver enzymes), an individual's personal baseline range is typically narrower than standard population-based reference intervals.

2:34:45supportedhighWhy the Next 10 Years May Add 50 to Your Lifespan | Dr. Dery

Continuous glucose monitors collect data at 5-minute intervals.

"With continuous glucose meter, I collect it every 5 minutes." (said at 2:34:45)

Commercial real-time continuous glucose monitoring (CGM) systems routinely measure and record interstitial glucose concentrations at 5-minute intervals, transmitting updated glucose values and trend indicators to a receiver or smartphone.

Fact-checked episodes

Publications